• About us
• Contact

Advertisement

Organisation › Details

Amatsigroup S.A.S

Amatsigroup, as a CDMO (Contract Development and Manufacturing Organization), provides preclinical and clinical stage services for the development of human and veterinary drugs. Amatsigroup, founded in 2010, was formed through the merger of four companies (Avogadro, Amatsi, DBI, Avepharm) bringing complementary expertise. As of 2014, Amatsigroup began to expand internationally with the acquisition of its subsidiaries SEPS Pharma in Belgium and Amatsigroup Inc. (Indiana, USA). Its international expansion continued in 2015 with the acquisition of Pierre Fabre's pharmaceutical analysis laboratory in Saint-Augustin, France. With more than 240 highly qualified staff and a diversified clientele of 300 international pharmaceutical groups and biotech companies, Amatsigroup is the leading provider of services for the development of veterinary and human pharmaceutical products. Amatsigroup contributed to the development and registration of more than 30 drugs for use in human health clinical trials and more than 20 in animal health. Amatsigroup provides its customers with a broad array of international services in five core business areas: > Bioservices: PK, ADME, residues, tolerance studies and preclinical and clinical bioanalysis. > Pharmaceutical analysis solutions: analytical method development and validation, stability studies, quality control on API and drug products. > Formulation development and manufacturing: galenic development, non-sterile and sterile trial and clinical batch manufacturing. > Clinical trial supply ¦ Packaging and logistics: GMP storage, packaging, labeling, QP release and worldwide distribution. > Biologicals: bioprocesses, biomanufacturing and control. *

 

	Start	2010-01-01 merged
	Group	Eurofins (Group)
	Industry	contract manufacturing (drugs)
	Industry 2	drug development services
	Street	2 bis avenue de Gascogne
	City	31470 Fontenilles
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2017-07-10)
	Currency	EUR
	Annual sales	60,000,000 (revenues, planned (2017) 2017-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Eurofins (Group)

• [1] Eurofins Scientific SE. (5/31/22). "Press Release: Eurofins Enhances Its Clinical and BioPharma Service Offering in Japan with Immune Repertoire Analysis Technology Through the Acquisition of Repertoire Genesis Inc.". Luxembourg....
• [2] Berkeley Lights, Inc.. (3/9/22). "Press Release: Berkeley Lights Announces Appointment of Dr. Siddhartha Kadia as Chief Executive Officer". Emeryville, CA....
• [3] Waters Corporation. (11/2/20). "Press Release: Waters Gives More Laboratories Access to Mass Spectrometry with Rapid, Easy, and Compact Radian ASAP System". Milford, MA....
• [4] Eurofins Scientific. (4/16/20). "Press Release: Eurofins Genomics Launches »SARS-CoV-2 Full-length Genome Sequencing« Service to Support Researchers Globally in Their Fight against the COVID-19 Pandemic and Outbreak Source Tracing". Ebersberg....
• [5] Eurofins Genomics LLC. (8/6/19). "Press Release: Eurofins Genomics US Expands Gene Synthesis Capabilities with Acquisition of Blue Heron Biotech". Louisville, KY....
• [6] Eurofins Scientific. (6/25/19). "Press Release: Eurofins Expands Its Transplantation Testing Footprint with the Acquisition of Transplant Genomics Inc.". Luxembourg....
• [7] Eurofins Scientific. (6/24/19). "Press Release: Operations Returning to Normal After the Cyber Attack Announced on June 3, 2019". Luxembourg....
• [8] Eurofins Scientific. (3/5/19). "Press Release: Eurofins Delivers Solid FY 2018 Results with Revenues of EUR 3,781m (+27% yoy) and Adjusted EBITDA of EUR 720m (19.0% of revenues), in Line with Its Recently Upgraded Objectives"....
• [9] Eurofins Scientific. (12/5/18). "Press Release: Eurofins Expands Its Footprint in Advanced Materials Sciences Through an Outsourcing Agreement with Signify (formerly: Philips Lighting) in the Netherlands"....
• [10] Eurofins Scientific. (11/26/18). "Press Release: Eurofins Further Reduces Its Financing Costs after Redeeming Its EUR 300m November 2018 Eurobond and Extends Its Organic Growth Objectives beyond 2020"....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.